Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EPOW vs VTAK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VTAK Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 5–2 Matrix Metrics)

VTAK Overall Winner 6-Pillar Tally: EPOW 2 – 2 VTAK (2 Tie) Matrix Metrics: EPOW 2 – 5 VTAK

As of Nov 16, 2026, Catheter Precision, Inc. (VTAK) is the stronger overall head-to-head candidate over Sunrise New Energy Co., Ltd Class A (EPOW) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). EPOW carries a Unified Composite Score of 47.1/100 (HOLD) at $3.30 (N/M Forward P/E, -34.5% operating margin), whereas VTAK carries 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin).

  • Technical & Structure Timing Caution: EPOW trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.2); meanwhile VTAK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EPOW vs VTAK
EPOW NASDAQ
Sunrise New Energy Co., Ltd Class A Ordinary Shares
Miscellaneous Electrical Machinery, Equipment & Supplies
$3.30
+1.54% 1D
Market Cap $8.3M
TTM Revenue $46M
Forward P/E N/M
Beta / 30D Vol -2.79β · 147% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 40.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.2 · SMA20: $3.67 · SMA50: $3.40
VTAK NYSE American Head-to-Head Winner
Catheter Precision, Inc.
Surgical & Medical Instruments & Apparatus
$0.15
-0.66% 1D
Market Cap $548,639
TTM Revenue $1.9M
Forward P/E N/M
Beta / 30D Vol 0.19β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 72.0 Fund 70.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -53.4%), weak momentum, RSI 33
RSI-14: 33.2 · SMA20: $0.16 · SMA50: $0.21

6-Pillar Scorecard Institutional Category Breakdown (EPOW 2 – 2 VTAK)

Columns: Metric · EPOW · VTAK
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.2x 0.3x
2. Growth & Scale VTAK
Revenue Growth (YoY) -56.8% +380.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $46M $1.9M
Market Cap $8.3M $548,639
3. Profitability & Quality VTAK
Gross Margin -12.6% 47.7%
Operating Margin -34.5% -388.1%
Net Profit Margin -35.8% 0.0%
Return on Equity (ROE) -123.5% -111.3%
4. Balance Sheet & Cash Flow EPOW
Cash Generation (TTM) -$9.6M EBITDA -$10M EBITDA
Cash Flow Margin -20.8% EBITDA Mgn N/A
Net Cash / Leverage -123.5% ROE $4.87 Book/Sh · -111.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat EPOW
OpEx & R&D Intensity 21.9% of Rev ($10M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Electrical Equipment & Parts Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EPOW (2) vs VTAK (5)
Institutional Metric EPOW VTAK Criterion Row Edge
Market Capitalization
Scale
$8.3M $548,639 Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-56.8% +380.7% Higher Growth VTAK
Operating Margin (TTM)
Profitability
-34.5% -388.1% Higher Margin EPOW
Net Profit Margin
Profitability
-35.8% 0.0% Higher Margin VTAK
Return on Equity (ROE)
Capital Efficiency
-123.5% -111.3% Higher ROE VTAK
52-Week Range Position
Momentum
41% ($0–$8) 1% ($0–$3) Stronger Trend EPOW
Beta / 30D Volatility
Risk Regime
-2.79β · 147% Vol 0.19β · 76% Vol Lower Realized Risk VTAK
Unified Institutional Score
Composite Signal
47.1 / 100 (HOLD) 58.1 / 100 (HOLD) Higher Composite VTAK
Trailing 12M Revenue (USD)
Operating Scale
$46M $1.9M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-12.6% 47.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.2x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.6M EBITDA (-123.5% ROE) -$10M EBITDA ($4.87 Book/Sh · -111.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EPOW +963.66 pp
EPOW: +938.9% · VTAK: -24.76%
3M Horizon EPOW +672.09 pp
EPOW: +591.8% · VTAK: -80.29%
6M Horizon EPOW +491.22 pp
EPOW: +407.46% · VTAK: -83.76%
1Y Horizon EPOW +362.81 pp
EPOW: +270.18% · VTAK: -92.63%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EPOW vs VTAK. Trailing 12-month operating profitability (EPOW -34.5% vs VTAK -388.1%) and valuation multiples (EPOW N/M vs VTAK N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EPOW ADR TTM Benchmark FX-Normalized USD
TTM Revenue$46M
Gross Margin-12.6%
Op. Margin-34.5%
ROE / Fwd P/E-123.5% · N/M
VTAK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.9M
Gross Margin47.7%
Op. Margin-388.1%
ROE / Fwd P/E-111.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EPOW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EPOW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VTAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EPOW Moat Profile Cyclical / Execution-Driven Positioning
Electrical Equipment & Parts Operator
Competes within the Electrical Equipment & Parts value chain with $8.3M market capitalization and -34.5% operating margin.
OpEx & R&D Reinvestment 21.9% of Rev ($10M)
90D Engineering Disclosures 0 Published
VTAK Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $548,639 market capitalization and -388.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EPOW vs VTAK Key Questions & Quantitative Answers

As of Nov 16, 2026, Catheter Precision, Inc. (VTAK) is the stronger overall head-to-head candidate over Sunrise New Energy Co., Ltd Class A (EPOW) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). EPOW carries a Unified Composite Score of 47.1/100 (HOLD) at $3.30 (N/M Forward P/E, -34.5% operating margin), whereas VTAK carries 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin). Technical & Structure Timing Caution: EPOW trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.2); meanwhile VTAK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VTAK leads the Growth & Scale pillar: EPOW posts -56.8% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (-12.6% gross margin, -34.5% operating margin), compared with VTAK at +380.7% YoY revenue growth and +0.0% YoY earnings growth on $1.9M TTM revenue (47.7% gross margin, -388.1% operating margin). On trailing 12-month operating scale, EPOW generates $46M in USD-normalized revenue versus $1.9M for VTAK. In operating R&D and SG&A reinvestment, EPOW deploys 21.9% of Rev ($10M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VTAK.

EPOW and VTAK trade at balanced relative valuation multiples. EPOW trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.2x EV/Revenue (-20.8% EBITDA margin), whereas VTAK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EPOW (-123.5% ROE) versus VTAK (-111.3% ROE) capital efficiency.

In options market volatility and institutional positioning, EPOW carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-2.79β · 147% Vol realized risk). By comparison, VTAK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.